Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-25-017945
Filing Date
2025-02-11
Accepted
2025-02-11 16:30:07
Documents
2
Period of Report
2025-02-11

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 4167
2 EX-24.1 krro-ex24_1.htm EX-24.1 14173
  Complete submission text file 0000950170-25-017945.txt   19923
Mailing Address 60 FIRST STREET 2ND FLOOR, SUITE 250 CAMBRIDGE MA 02141
Business Address 60 FIRST STREET 2ND FLOOR, SUITE 250 CAMBRIDGE MA 02141 617-468-1999
Korro Bio, Inc. (Issuer) CIK: 0001703647 (see all company filings)

EIN.: 472324450 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O KORRO BIO, INC. 60 FIRST STREET, 2ND FLOOR, SUITE 250 CAMBRIDGE MA CAMBRIDGE
Business Address
Dolan Oliver (Reporting) CIK: 0002053835 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39062 | Film No.: 25610258